| Website | paramountcapital.com |
| Phone | (212) 554-4300 |
| Employees |
Paramount BioSciences is a global pharmaceutical development and healthcare investment firm that conceives, nurtures, and supports new biotechnology and life-sciences companies.
The company has a keen eye for finding and developing novel therapeutic medicines that have, in our opinion, significant market potential. It assesses promising drug candidates from around the globe, from academic centers to biotechnology firms to pharmaceutical companies. Once compounds are in-licensed, selected members of the Paramount BioSciences Executive Team – each member has significant life sciences industry experience, as described in their bios – supported by approximately 80 in-house professionals, manages their entire development cycle, supporting all aspects of drug development including manufacturing, formulation, technology transfer, pharmacology, toxicology, clinical development, regulatory, quality assurance, commercialization, and life cycle management.
After technologies are in-licensed and management teams are recruited to run portfolio companies built around novel therapeutics, Paramount BioSciences arranges for financing through its affiliate Paramount BioCapital, Inc., a FINRA registered broker-dealer. The affiliate’s financial professionals have experience with securities and corporate transactions, including financings and mergers and acquisitions.
| Company | Date | Round | Size | Participants |
| CEL-SCI | 8/09 | Venture Round | $4.4M | 7 |
| Genelabs Technologies | 6/06 | Venture Round | $8.3M | 5 |
